- Transaction eliminates $11.2 million in debt, strengthening financial position - HUNTSVILLE, AL, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today announced the sale of its UniverXome subsidiary. The transaction was finalized on December 23, 2024 and eliminated $11.2 million in associated subsidiary-level debt, positioning Serina with a debt-free balance ...

Board of Directors Update - Karen J Wilson appointed to the Board of Directors bringing over three decades of leadership experience in the life sciences sector [1][3] - Steven Mintz departed from the Board of Directors after contributing to the company's transition from private to public [4] POZ Platform Technology - Proprietary POZ technology based on poly(2-oxazoline) polymer enables greater control in drug loading and precision in drug release rate [5] - POZ technology aims to improve pharmacokinetic profiles of drugs with narrow therapeutic windows [5] - Potential applications across a broad range of payloads and indications with ongoing out-licensing and partnership arrangements including a non-exclusive license agreement with Pfizer [6] Company Overview - Clinical-stage biotechnology company developing wholly owned drug product candidates for neurological diseases and other indications [7] - POZ Platform technology has potential to improve efficacy and safety profiles of small molecules RNA-based therapeutics and antibody-based drug conjugates [7] - Headquarters located in Huntsville Alabama on the campus of the HudsonAlpha Institute of Biotechnology [7]

Meet with Serina's CEO Steven A. LedgerParkinson's disease is a progressive neurological disorder that primarily affects movementContinuous dopaminergic stimulation (CDS) has been shown to reduce the severity of motor complications (dyskinesia) in advanced Parkinson's patientsDiscussion of the Serina IND candidate's target product profile versus the current standard of care in providing CDS HUNTSVILLE, AL, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage bi ...

Core Viewpoint - Serina Therapeutics is advancing its proprietary POZ Platform drug delivery technology aimed at improving treatment for Parkinson's disease through continuous dopaminergic stimulation (CDS) [1][4]. Company Overview - Serina Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases and other indications [4]. - The company is headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology [4]. Upcoming Event - CEO Steven A. Ledger will present at Tribe Public's webinar titled "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on December 18, 2024 [1]. - The event will allow participants to submit questions to the CEO, enhancing engagement with stakeholders [3]. Technology and Product Development - Serina's POZ Platform aims to enhance the efficacy and safety profiles of various therapeutic modalities, including small molecules, RNA-based therapeutics, and antibody-drug conjugates (ADCs) [4].

HUNTSVILLE, AL, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, announced that Serina Therapeutics' Chief Development Officer, Randall Moreadith, MD, PhD, will be presenting today at the 3rd Annual LNP Immunogenicity & Toxicity Summit in Boston, MA. Entitled "Overcoming Anti-PEG Antibody Responses – A Novel PEOZ-lipid That Fails to Elicit an Immune Response t ...

HUNTSVILLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced a $10 million equity financing with strategic shareholder JuvVentures (UK) Limited. The transaction provides Serina with funding to continue advancing SER-252 (POZ-apomorphine), enabled by its proprietary POZ Platform™ drug optimization technology, into a Phase 1 clinical trial in advanced Parkinson's disease patients in the second half of 2025. Und ...

Revenue and Financial Performance - Revenues for Q3 2024 were $14 thousand, a decrease from $29 thousand in Q3 2023[3] - Total revenues for September 2024 were $14 million, a decrease from $29 million in September 2023[22] Operating Expenses - Operating expenses for Q3 2024 increased to $5.3 million from $1.5 million in Q3 2023[3] - General and administrative expenses for Q3 2024 increased to $2.9 million from $0.9 million in Q3 2023[5] - Net loss from operations was $(5.312) million in September 2024, compared to $(1.463) million in September 2023[22] Research and Development - Research and development expenses for Q3 2024 rose to $2.4 million, up from $0.6 million in Q3 2023[4] - Research and development expenses increased to $2.415 million in September 2024 from $603 thousand in September 2023[22] Net Income and Loss - Net income for Q3 2024 was $1.4 million, compared to $1.8 million in Q3 2023[7] - Change in fair value of warrants contributed $6.669 million to other income in September 2024, up from $596 thousand in September 2023[22] Cash and Liquidity - Cash, cash equivalents, and restricted cash totaled $3.2 million as of September 30, 2024[8] - The company anticipates insufficient cash to meet operating needs for the next 12 months, raising substantial doubt about its ability to continue as a going concern[9] - Net cash used in operating activities was $(12.548) million for the period ending September 2024, compared to $(2.597) million in the same period of 2023[23] - Cash, cash equivalents, and restricted cash decreased by $4.384 million to $3.235 million at the end of September 2024[23] Financing Activities - Proceeds from the exercise of Post-Merger Warrants by Juvenescence amounted to $4.988 million in September 2024[23] - Net cash provided by financing activities was $8.181 million in September 2024, down from $10.080 million in September 2023[23] - Issuance of common stock upon conversion of Preferred Stock totaled $36.404 million in September 2024[23] - Merger and issuance of common stock upon consummation of Merger on March 26, 2024, amounted to $961 thousand[23] Assets and Liabilities - Total assets as of September 30, 2024, were $7.435 million, down from $8.968 million at the end of 2023[18] Product Development and Partnerships - SER-252, an investigational apomorphine therapy, is planned for clinical testing in 2025[10] - The POZ Platform™ technology has potential for broad applications, including a non-exclusive license agreement with Pfizer for LNP drug delivery formulations[12]

HUNTSVILLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, today announced its financial results for the third quarter ended September 30, 2024, along with key recent updates. Recent Highlights Partnership and Presentations with Enable Injections: Building on its collaboration wit ...

Table of Contents Title of each class Trading Symbol Name of exchange on which registered Common Stock, par value $0.0001 per share SER NYSE American UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ...

HUNTSVILLE, AL, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, announced that it has made grants of options to purchase an aggregate of 60,500 shares of Serina’s common stock to three new non-executive employees on November 6, 2024 (each, an “Option Grant”). Each Option Grant has ...